Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Biofunctionalities of unprocessed and processed flours of Australian lupin cultivars: Antidiabetic and organ protective potential studies.

Tytuł:
Biofunctionalities of unprocessed and processed flours of Australian lupin cultivars: Antidiabetic and organ protective potential studies.
Autorzy:
Mazumder K; Department of Pharmacy, Jashore University of Science and Technology, Jashore-7408, Jashore, Bangladesh; School of Biomedical Sciences and Graham Centre for Agricultural Innovation, Charles Sturt University, Boorooma St, Wagga Wagga, NSW, Australia. Electronic address: .
Rabiul Hossain M; Department of Pharmacy, Faculty of Basic Medical and Pharmaceutical Sciences, University of Science and Technology Chittagong, Foy's Lake, Chittagong 4202, Bangladesh.
Aktar A; Department of Pharmacy, Jashore University of Science and Technology, Jashore-7408, Jashore, Bangladesh.
Dash R; Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.
Farahnaky A; School of Biomedical Sciences and Graham Centre for Agricultural Innovation, Charles Sturt University, Boorooma St, Wagga Wagga, NSW, Australia; Biosciences and Food Technology, School of Science, RMIT University, Bundoora West Campus, Plenty Road, Melbourne, Vic 3083, Australia.
Źródło:
Food research international (Ottawa, Ont.) [Food Res Int] 2021 Sep; Vol. 147, pp. 110536. Date of Electronic Publication: 2021 Jun 16.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Ottawa, Ontario, Canada : Published on behalf of the Canadian Institute of Food Science and Technology by Elsevier Applied Science, c1992-
MeSH Terms:
Flour*
Hypoglycemic Agents*/pharmacology
Animals ; Australia ; Plant Extracts/pharmacology ; Rats ; Rats, Wistar
Contributed Indexing:
Keywords: Actinomycin C2; Diabetes mellitus; Functional food; Molecular mechanics/generalized Born volume integration (MM/GBVI) model; α-Amylase; α-Glucosidase
Substance Nomenclature:
0 (Hypoglycemic Agents)
0 (Plant Extracts)
Entry Date(s):
Date Created: 20210817 Date Completed: 20210906 Latest Revision: 20210906
Update Code:
20240104
DOI:
10.1016/j.foodres.2021.110536
PMID:
34399513
Czasopismo naukowe
As lupin has emerged popularity as dietary protein and nutritional source, our present research was aimed to demonstrate the antidiabetic and organ-protective activities of nine cultivars of Australian sweet lupin seed flours by means of in vitro and in vivo assays accompanied by identification of their bioactive phytocompounds and exploration of underlying mechanisms of their hypoglycemic activity using in silico approach. In vitro α-amylase and α-glucosidase activities inhibition and glucose uptake assays identified Jenabillup seed flours for exhibiting the most potential antidiabetic activity amongst the nine cultivars. In vivo antidiabetic and major organ-protective activities were investigated on streptozotocin-induced hyperglycemia and organ damages in Wister rat model. Along with attenuating hyperglycemia and retreating major organ damages, the biochemical imbalance in cardiac, hepatic and renal markers were well-balanced by Jenabillup seed flours treatment. These activities of lupin seed flours were insignificantly affected by thermal processing. Moreover, in silico investigation of 106 phytochemicals identified by gas chromatography-mass spectroscopy (GC-MS) analysis of the seed flour extracts of nine cultivars revealed that more than 35% of compounds possess moderate to high binding affinity to α-amylase and α-glucosidase enzymes. These bioactive compounds act synergistically to exert potential hypoglycemic activity. Cross-docking and binding energy calculation by molecular mechanics/generalized Born volume integration (MM/GBVI) model suggest actinomycin C2 as a potential inhibitor of both α-amylase and α-glucosidase enzymes. These findings acclaim that Australian sweet lupin seed flours may be considered not only as functional food, but also for further development of effective drugs in pharmaceuticals in the treatment of diabetes mellitus and resultant organ damages.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies